Cargando…
Older patients are still under-represented in clinical trials of Alzheimer’s disease
BACKGROUND: The age gap between participants in trials and patients who could benefit from the drugs studied has been widely documented across different clinical areas. Patients with dementia included in clinical research are systematically younger than those in the general population. We examined t...
Autores principales: | Banzi, Rita, Camaioni, Paolo, Tettamanti, Mauro, Bertele’, Vittorio, Lucca, Ugo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982205/ https://www.ncbi.nlm.nih.gov/pubmed/27520290 http://dx.doi.org/10.1186/s13195-016-0201-2 |
Ejemplares similares
-
Estrogens still represent an attractive therapeutic approach for Alzheimer’s disease
por: Tamagno, Elena, et al.
Publicado: (2021) -
Mortality Prediction in the Oldest Old with Five Different Equations to Estimate Glomerular Filtration Rate: The Health and Anemia Population-based Study
por: Mandelli, Sara, et al.
Publicado: (2015) -
MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort
por: Da Vià, Matteo Claudio, et al.
Publicado: (2022) -
Can Anti–β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?
por: Imbimbo, Bruno P., et al.
Publicado: (2020) -
NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease
por: Lawlor, Brian, et al.
Publicado: (2014)